ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Probiotics for pediatric diarrhea and constipation: an umbrella meta-analysis.BMC pediatrics · 2025Pooled it
- Global research trends in bacteriophage and gut microbiota: a bibliometric and visual analysis from 2012 to 2025.Frontiers in microbiology · 2025Pooled it
- Trial
- Effect of AG1Frontiers in nutrition · 2026Trial
- Virobiome-mediated regulation of microbiota-gut-brain axis signaling and neuroimmune homeostasis.Cell communication and signaling : CCS · 2026Review
- Targeting the Microbiota-Gut-Brain Axis: Emerging Nanomedicine Approaches for Neurodegenerative Diseases.The European journal of neuroscience · 2026Review
- Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities.iScience · 2026Review
- Live and Heat-InactivatedNutrients · 2026Article
- Psychobiotics and the microbiota-gut-brain axis: Emerging paradigms in mental health modulation.Experimental physiology · 2026Review
- The Gut Microbiota and Autism Spectrum Disorder: Current Research and Therapeutic Insights.Behavioral sciences (Basel, Switzerland) · 2026Review
- Sustainable nanomaterials for precision dental medicine: green synthesis, therapeutic applications, and future directions.Journal of nanobiotechnology · 2026Review
- Enteric Infections, Dysbiosis, and Metabolic Dysfunction: The Role of Diarrheagenic Pathogens in Insulin Resistance.International journal of molecular sciences · 2026Review
- Imbalance of the Brain-Gut-Microbiota Axis in Major Depressive Disorder: From Pathogenesis to Clinical Translation.Neuropsychiatric disease and treatment · 2026Review
- The gut-brain axis in pharmacology: microbiome-driven modulation of CNS drugs and neuropsychiatric outcomes.Frontiers in pharmacology · 2026Review
- Link between physical activity, nutrition, and antimicrobial pharmacokinetics and therapeutic efficacy: Implications for resistance management.SAGE open medicine · 2026Review
- Pharmacological interventions targeting the gut-brain axis in neurological disorders: mechanisms and translational applications.Frontiers in neuroscience · 2026Review
- Targeting the gut-immune-brain axis: pharmacological insights from depression in inflammatory bowel disease.Frontiers in pharmacology · 2026Review
- Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities.Frontiers in pharmacology · 2026Review
- Psychological stress and eating behaviors as interacting influences on patient-reported disease activity in Italian patients with inflammatory bowel disease.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The modulation of gut microbiota presents promising therapeutic possibilities for various health conditions, ranging from gastrointestinal infections to neurodegenerative and mental health disorders. Among the available interventions, gut microbiota modulators (GMMs) such as probiotics and prebiotics have demonstrated significant potential in infection prevention and neuroprotection. Despite these encouraging findings, the clinical application of GMMs remains challenging due to safety concerns and inconsistent effectiveness across diverse patient populations. These factors create substantial barriers to the widespread adoption of microbiota-based therapies in clinical practice. To overcome these challenges and fully leverage the therapeutic potential of microbiota modulation, this review explores the feasibility of repurposing GMMs for managing multiple health disorders. A broad spectrum of microbiota-targeted strategies is examined, including dietary modifications, fecal microbiota transplantation, bacteriophage therapy, microbiome engineering, and immune system modulation. A particularly innovative approach involves integrating GMMs with pharmaceutical delivery systems to enhance therapeutic efficacy while mitigating potential adverse effects. This integrative strategy underscores the pivotal role of the gut microbiome in health and disease, supporting the development of precision medicine tailored to individual patient needs. By combining GMMs with targeted delivery mechanisms, this approach not only improves treatment effectiveness but also addresses critical concerns regarding safety and patient variability. Furthermore, this review outlines future research directions within the rapidly evolving field of microbiota modulation, emphasizing the necessity of comprehensive clinical trials and long-term safety evaluations. By critically assessing both the challenges and opportunities associated with microbiota-based interventions, this study provides a strategic framework for translating experimental research into viable clinical applications. A holistic approach to gut microbiota modulation has the potential to redefine treatment paradigms, offering personalized therapeutic strategies for a wide range of disorders and advancing the broader field of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.